Latest News
PUBLICATION OF ONE YEAR OUTCOMES FROM PROMISE I U.S. STUDY OF THE LIMFLOW SYSTEM DEMONSTRATES EXCELLENT SUSTAINED AMPUTATION-FREE SURVIVAL AND WOUND HEALING IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA
Twelve-Month Results Published in the Journal of Vascular Surgery Paris, May 20, 2021 — LimFlow SA, the pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the publication of 12-month data from the full patient cohort in its PROMISE […]
LIMFLOW RECEIVES JAPAN PMDA APPROVAL FOR CLINICAL STUDY OF MINIMALLY-INVASIVE TECHNOLOGY DESIGNED TO PREVENT AMPUTATIONS IN CHRONIC LIMB-THREATENING ISCHEMIA PATIENTS
PARIS – March 23, 2020 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved its Clinical Trial Notification (CTN) for the Japanese cohort of […]
LimFlow System Demonstrates Excellent Sustained Amputation-Free Survival and Wound Healing at One Year in PROMISE I U.S. Study
LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), today announced publication of positive two-year data from the ALPS Registry of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System.
Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia
LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), today announced publication of positive two-year data from the ALPS Registry of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System.
First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-Threatening Ischemia
LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the first patient has been treated in its PROMISE II U.S. pivotal trial of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System.
LimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population
LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the LimFlow Percutaneous Deep Vein Arterialization System.
Limflow Receives FDA Approval for U.S. Pivotal Study of Minimally-Invasive Technology Designed to Prevent Amputations in Chronic Limb-Threatening Ischemia Patients
LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption for the PROMISE II pivotal study of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System.
LimFlow Raises €27 Million ($33.5 Million) in Series C Financing Led by Sofinnova Partners to Advance Innovative Critical Limb Ischemia (CLI) Treatment
LimFlow SA, developer of innovative, peripheral endovascular technology transforming the treatment of critical limb ischemia (CLI), today announced it has secured €27 million ($33.5 million) in an oversubscribed Series C financing.
LimFlow Nominates Pierre Guyot as Chairman of Board of Directors and Expands Senior Management Team
LimFlow SA, a Paris-based medical device company dedicated to transforming treatment options for Critical Limb Ischemia (CLI), announced today changes to their board of directors by naming Pierre Guyot as the new chairman of the board.
LimFlow Completes Enrollment In US Feasibility Study and Receives Breakthrough Device Status from FDA for Its Percutaneous Deep Vein Arterialization (pDVA) System
LimFlow SA, developer of minimally-invasive technology for the treatment of end-stage critical limb ischemia (CLI), today announced completion of enrollment of the original 10-patient cohort in the U.S. feasibility study of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System.
LimFlow Announces Publication of Positive Results from Pilot Study of LimFlow Percutaneous Deep Vein Arterialization (pDVA) System
LimFlow SA today announced publication of positive results from the pilot study of the LimFlow Percutaneous Deep Vein Arterialization System (pDVA) in the July issue of the Journal of Endovascular Therapy.
LimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study
LimFlow SA today announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System, a novel, purely percutaneous device for the treatment of end-stage critical limb ischemia (CLI) when all other revascularization efforts have been exhausted.
Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia
LimFlow SA, developer of minimally-invasive technology for the treatment of end-stage critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD), today announced the expansion of the company’s senior management team.
LimFlow Expands Senior Management Team and Opens Silicon Valley Office
LimFlow SA, developer of minimally-invasive technology for the treatment of end-stage critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD), today announced the expansion of the company’s senior management team.
LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients
LimFlow SA, developer of minimally-invasive technology for the treatment of end-stage critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD), announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption for a feasibility study of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System.
LimFlow Receives CE Mark for Purely Percutaneous Critical Limb Ischemia (CLI) Technology Designed to Restore Perfusion for “No Option” Patients
LimFlow SA, developer of endovascular technology transforming the treatment of critical limb ischemia (CLI), today announced that it received the CE Mark (Conformité Européenne) for its fully percutaneous LimFlow System designed for venous arterialization of the lower limbs in end-stage patients at risk of limb amputation for CLI.
LimFlow Announces Presentation of the LimFlow Procedure at a Dedicated Symposium During the Leipzig Interventional Course, LINC 2015 – January 27-30, 2015
LimFlow today announced that Drs. Andrej Schmidt and Jihad Mustapha will be chairing a session on the LimFlow procedure for treating Critical Limb Ischemia at the upcoming Leipzig Interventional Course or LINC on Tuesday 27 January 2015 starting at 16:00 CET.
LimFlow Announces the Closing of Series A Financing
LimFlow today announced that it has closed its Series A financing with a major Family Fund leading the round. The terms and amount were not discussed.